Group 1 - The core point of the news is that Hansoh Pharmaceutical (03692.HK) has successfully added two new indications for its innovative drug Amelot, which will be included in the updated National Medical Insurance Drug List for 2025, effective from January 1, 2026 [1] - The stock has received a majority of "buy" ratings from investment banks, with four firms issuing buy ratings in the last 90 days and an average target price of HKD 44.49 [1] - Huatai Securities recently issued a report giving Hansoh Pharmaceutical a buy rating with a target price of HKD 43.23 [1] Group 2 - Hansoh Pharmaceutical has a market capitalization of HKD 244.99 billion, ranking first in the chemical pharmaceutical industry [2] - Key performance indicators show that Hansoh has a Return on Equity (ROE) of 16.34%, significantly higher than the industry average of -11.38%, and a net profit margin of 42.17%, compared to the industry average of -34.83% [2] - The company also boasts a gross margin of 91.11%, which is well above the industry average of 50.96%, and a debt ratio of 11.33%, much lower than the industry average of 39.81% [2]

Core Insights - Hansoh Pharmaceutical (03692) announced that its innovative drug Amivantamab has successfully added two new indications to the 2025 National Medical Insurance Directory, which will be implemented on January 1, 2026 [1][2] Group 1: New Indications for Amivantamab - Amivantamab (brand name: 阿美乐) has received approval for two new indications for the treatment of adult non-small cell lung cancer (NSCLC) patients with specific EGFR mutations [1] - The new indications include treatment for patients who have previously undergone surgical resection and for those with locally advanced, unresectable NSCLC who have not shown disease progression during or after platinum-based chemotherapy [1] Group 2: Renewal of Other Drugs in the National Medical Insurance Directory - The drug Pemigatinib (brand name: 圣罗莱) has had its two indications renewed for inclusion in the 2025 National Medical Insurance Directory, specifically for treating anemia caused by chronic kidney disease [2] - The drug Adefovir Dipivoxil (brand name: 恒沐) has also been renewed for chronic hepatitis B treatment in adult patients [2] - Other innovative drugs such as Fluoromethylphenyl (brand name: 豪森昕福), Pegylated Liraglutide (brand name: 孚来美), and Inotuzumab Ozogamicin (brand name: 昕越) are currently under the National Medical Insurance Directory agreement until December 31, 2026 [2]

Core Insights - Hansoh Pharmaceutical (03692) announced that its innovative drug Amivantamab has successfully added two new indications to the 2025 National Medical Insurance Directory, effective January 1, 2026 [1][2] - The drug Pemigatinib (brand name: Saintrolai) has renewed its inclusion in the 2025 National Medical Insurance Directory for two indications related to anemia caused by chronic kidney disease [1] - The drug Adefovir Dipivoxil (brand name: Hengmu) has also renewed its inclusion for the treatment of chronic hepatitis B in adults [2] Summary by Category New Indications - Amivantamab (brand name: Amivale) has received approval for two new indications for the treatment of adult non-small cell lung cancer (NSCLC) patients with specific EGFR mutations [1] - The new indications include treatment for patients who have undergone surgical resection and those with locally advanced, unresectable NSCLC [1] Renewed Inclusion - Pemigatinib (brand name: Saintrolai) has renewed its inclusion for treating anemia in adults with chronic kidney disease, covering both non-dialysis and dialysis patients [1][2] - Adefovir Dipivoxil (brand name: Hengmu) has renewed its inclusion for chronic hepatitis B treatment in adults [2] Other Relevant Drugs - Other innovative drugs such as Fluoromethylphenidate (brand name: Haosenxinfu), Pegylated Liraglutide (brand name: Fulaimai), and Inalizumab (brand name: Xinyue) are currently under the National Medical Insurance Directory agreement until December 31, 2026 [2]

Core Viewpoint - The Hu Run Research Institute released the "2025 Hu Run Women Entrepreneurs List," highlighting that Zhong Huijuan and her daughter Sun Yuan topped the list as China's richest women with a wealth of 141 billion yuan, marking an increase of 64 billion yuan or 83% from the previous year. This is the first time a woman from the life and health sector has achieved this status [1][3]. Company Overview - Zhong Huijuan, 64, is from Lianyungang, Jiangsu, and is married to Sun Piaoyang, the founder of Heng Rui Medicine. Together, they are known as "China's most powerful pharmaceutical couple," each leading companies with market values exceeding 100 billion yuan [3]. - Over the past year, Hansoh Pharmaceutical's market value doubled, driven by the launch of innovative drugs and international collaborations. Since 2025, the company's stock price has increased by over 115%, reaching 35.78 HKD per share, with a market capitalization of 216.65 billion HKD [3][4]. Business Transformation - Hansoh Pharmaceutical transitioned from a generic drug manufacturer to a leader in innovative drugs, reflecting the evolution of China's pharmaceutical industry over the past three decades. As of the first half of 2025, innovative drug revenue accounted for 82.7% of total revenue, with frequent overseas licensing deals [3][7]. - The company faced significant challenges due to the implementation of centralized drug procurement policies, which drastically reduced profits from generic drugs. In response, the company shifted its focus to innovative drug development, increasing R&D investments and establishing multiple research centers [7][10]. Financial Performance - In 2024, Hansoh Pharmaceutical reported total revenue of 12.261 billion yuan, a year-on-year increase of 21.3%, with a net profit of 4.372 billion yuan, up 33.4%. Innovative drug and collaboration product sales reached 9.477 billion yuan, a 38.1% increase, making up 77.3% of total revenue [8][10]. - For the first half of 2025, the company achieved revenue of 7.434 billion yuan, a 14.3% increase, and a net profit of 3.135 billion yuan, up 15%. Innovative drug sales further increased to 6.145 billion yuan, representing 82.7% of total revenue [8][10]. R&D Investment - Hansoh Pharmaceutical's commitment to R&D is evident, with R&D expenditures of approximately 2.702 billion yuan in 2024, a 28.8% increase, accounting for over 20% of total revenue. In the first half of 2025, R&D spending was about 1.441 billion yuan, up 20.4% [10]. - The company has over 1,800 R&D professionals and is advancing more than 70 innovative drug clinical trials across various therapeutic areas, including oncology and autoimmune diseases [10][11]. Licensing and Collaborations - International pharmaceutical giants have increasingly sought partnerships with Hansoh Pharmaceutical, leading to significant licensing agreements. Notable deals include a $1.85 billion upfront payment from GSK for ADC drug HS-20093 and a $1.12 billion upfront payment from Merck for GLP-1 receptor agonist HS-10535 [11]. - The company has established a "R&D-licensing-reinvestment" cycle, ensuring stable revenue growth while funding further research initiatives [11][12]. Market Position - The wealth increase of Zhong Huijuan and her daughter is largely attributed to the rise in Hansoh Pharmaceutical's stock price, which has surged over 115% since 2025. However, compared to other major domestic pharmaceutical companies, Hansoh remains relatively under the radar, focusing on R&D rather than media attention [12].